Huntington-kór: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• HTT 2
• NRF2 0
• BDNF 1
• STING 0
• AKT 0
• AMPK 1
• NLRP3 0
• SIRT1 0
• PI3K 0
• HMGB1 0
• PPAR 0
• C9orf72 0
• HDAC 0
• HIF-1 0
• HSP90 0
• NMDA 0
• TDP-43 0
• TLR4 0
• APP 0
• BCL-2 0
• CD30 0
• CFTR 1
• CTNNB1 0
• DMD 1
• ERK 0
• EZH2 0
• G6PD 0
• GLP-1 0
• GPX4 0
• IL-17 0
• JNK 0
• LRRK2 0
• MMP-9 0
• mTOR 0
• NF1 1
• PINK1 0
• PSEN1 0
• SMN1 1
• SOD1 0
• STAT3 0
• TP53 0
• YAP 0

573 intézményből 24, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NINDS · K99

  Post translational modifications as a therapeutic target for Huntington's Disease

  University of California-Irvine· Irvine, Egyesült Államok· 119 840 USD awarded in fiscal year 2026· until 2028. aug.

• NIH NIA · R43

  Non-Invasive Diagnostic Assays for Neurodegenerative Diseases

  Sonas Biotechnologies Inc· Eugene, Egyesült Államok· 499 745 USD awarded in fiscal year 2026· until 2027. szept.

• NIH NINDS · DP2

  RNA-Templated DNA Repair as a Genome Maintenance Pathway in Neurons

  University of Colorado Denver· Aurora, Egyesült Államok· 741 000 USD awarded in fiscal year 2026· until 2031. jún.

• NIH NINDS · R56

  The Mechanism of Trinucleotide Repeat Disease Expansions

  Ohio State University· Columbus, Egyesült Államok· 551 250 USD awarded in fiscal year 2026· until 2027. aug.

• NIH NINDS · RM1

  DECIPHERING THE MOLECULAR BASIS OF SOMATIC GAA-REPEAT DYNAMICS IN SCA27B

  University of Miami School of Medicine· Coral Gables, Egyesült Államok· 1 819 495 USD awarded in fiscal year 2026· until 2031. júl.

• European Commission (Horizon Europe) · HORIZON-ERC

  Ubiquitin Signaling as a Key Regulator of Aging and Neurodegeneration (UbiAge)

  Johann Wolfgang Goethe-Universitaet Frankfurt Am Main· Frankfurt Am Main, Németország· EU contribution 1 489 985 EUR· until 2032. márc.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Curation, Integration, Modelling and Rational Design of Small Molecule Amyloid Inhibitors (AmyStoppers)

  Vilniaus Universitetas· Vilnius, Litvánia· EU contribution 196 976 EUR· until 2029. márc.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  HDFACT82: Functional characterisation of CCDC82 and its interaction with FACT in Huntington’s disease

  Agencia Estatal Consejo Superior de Investigaciones Cientificas· Madrid, Spanyolország· EU contribution 194 075 EUR· until 2029. febr.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Treatment of depression and cognitive decline in Huntington's Disease: Cannabinoids as a Dual Therapeutic Approach (TACHD)

  Fundacio de Recerca Clinic Barcelona-Institut D Investigacions Biomediques August Pi I Sunyer· Barcelona, Spanyolország· EU contribution 194 075 EUR· until 2028. szept.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Astrocyte Exosome Cargo as a Mediator of Non-Cell-Autonomous Neurodegeneration in Huntington’s Disease (AstroExo-HD)

  Siec Badawcza Lukasiewicz - Port Polski Osrodek Rozwoju Technologii· Wrocaw, Lengyelország· EU contribution 179 006 EUR· until 2028. máj.

10 of 278 running projects, newest first. Listed amounts together: 149,0 M USD + 30,4 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Leállították

  Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington Disease

  NCT04400331· Neurocrine Biosciences· Frissítve: 2026. nov. 3.

  “Sponsor Decision”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  Facilitating Effective Eating With DoddleBags: A Single-Arm Acceptability Study Of DoddleBags to Assess Impact on Self Feeding Behaviours in a Huntington's Disease Population

  NCT07299682· University of Hull· Frissítve: 2026. máj. 28.

  “No recruitment”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Huntington's Disease

  NCT05655520· Supernus Pharmaceuticals, Inc.· Frissítve: 2025. dec. 17.

  “Internal company decision”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Couple and Spouse Caregiver in Huntington's Disease

  NCT04394767· University Hospital, Lille· Frissítve: 2025. máj. 16.

  “Sponsor's decision, no more inclusions made since the last extension”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Biological Sample Collection for Research and Biobanking

  NCT04270604· New York Stem Cell Foundation Research Institute· Frissítve: 2024. aug. 2.

  “The study was voluntarily terminated by the PI to focus efforts on an alternative biobanking protocol.”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  Safety and Tolerability Study With VY-HTT01, in Adults With Early Manifesting Huntington's Disease

  NCT04885114· Voyager Therapeutics· Frissítve: 2021. aug. 16.

  “We have discontinued our 1st generation HD program with the VYTAL Study \& have initiated a 2nd generation program using a novel, proprietary AAV capsid that may enable intravenous administration \& achieve widespread distribution to affected tissue.”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• Creatine and Beta-Hydroxy-Beta-Methylbutyrate (HMB) Supplementation Plus Home-Based Exercise for Sarcopenia in Huntington's Disease

  NCT07902206· Universidad de Burgos· Forrás

• Feasibility and Acceptability of an LLM-based Chatbot for Family Caregivers: Evaluation Study

  NCT07280650· University of Michigan· Forrás

• A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease

  NCT07326709· Novartis Pharmaceuticals· Forrás

• Real World Effectiveness and Safety of Deutetrabenazine in Adult Chinese Participants With Huntington's Disease (HD) Chorea in China

  NCT07601516· Teva Branded Pharmaceutical Products R&D LLC· Forrás

• GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease

  NCT05686551· Hoffmann-La Roche· Forrás

• HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease

  NCT02855476· University College, London· Forrás

• Safety and Tolerability Study of Human Neural Stem Cells for Huntington's Disease

  NCT07451613· Leslie Thompson· Forrás

• Autobiographical Memory, Future Thought, and Eye Movements in Huntington's Disease

  NCT07409597· University Hospital, Angers· Forrás

• Home-based TDCS (Transcranial Direct Current Stimulation) for Cognitive and Behavioral Symptoms in Huntington's Disease

  NCT06843252· The University of Texas Health Science Center at San Antonio· Forrás

• Project AWARE 2.0 to Improve Awareness, Willingness and Ability for Research and Enrollment in Clinical Research

  NCT06343220· Huntington Study Group· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 4
• Organoids 4
• CRISPR-Cas Systems 11
• Gene Expression Profiling 13
• Sequence Analysis, RNA 2
• Whole Genome Sequencing 1
• Proteomics 10
• Metabolomics 1
• Mass Spectrometry 1
• Immunohistochemistry 2
• Liquid Biopsy 1
• Positron-Emission Tomography 10
• Magnetic Resonance Imaging 28
• Machine Learning 11
• Deep Learning 4
• Cohort Studies 8
• Genome-Wide Association Study 6

• Cross-species single-cell atlas of the striatum defines cell-type and subregion disease vulnerabilities.

  Cell, 2026. szept.

• The genetic architecture of fibromyalgia across 2.5 million individuals.

  Nat Med, 2026. júl.

• Exploring shared genetic pathways and gene interplay in major neurodegenerative diseases: a comprehensive review.

  Gene, 2026. júl.

• The NeuroBioBank whole-genome catalogue of human brain donors with central nervous system disorders.

  Brain, 2026. júl.

• From genes to trajectories: mapping genetic influences on Huntington's disease progression.

  Bioinformatics, 2026. febr.

• Unbiased human genomic characterization of polyglutamine disorder genes to guide biological understanding and therapeutic strategies.

  HGG Adv, 2025. nov.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.